Edition:
India

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

43.00USD
19 Jan 2018
Change (% chg)

$0.54 (+1.27%)
Prev Close
$42.46
Open
$43.12
Day's High
$43.30
Day's Low
$41.51
Volume
315,919
Avg. Vol
38,016
52-wk High
$46.36
52-wk Low
$13.01

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $381.96
Shares Outstanding(Mil.): 13.01
Dividend: --
Yield (%): --

Financials

BRIEF-Urogen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

19 Jan 2018

BRIEF-Urogen Announces Proposed Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

17 Jan 2018

BRIEF-Urogen Pharma Q3 loss per share $0.02

* Urogen Pharma reports third quarter 2017 financial results and recent corporate developments

14 Nov 2017

BRIEF-Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​

* Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​ Source: (http://bit.ly/2hdmj4k) Further company coverage:

08 Nov 2017

BRIEF-Urogen Pharma receives FDA fast track designation for Mitogel

* Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC)

29 Aug 2017

BRIEF-UroGen Pharma Q2 loss per share $0.70

* UroGen Pharma reports second quarter 2017 financial results and recent corporate developments

15 Aug 2017

Earnings vs. Estimates